Lytix Biopharma AS (STU:6BG) EPS (Basic): €-0.09 (TTM As of Mar. 2026)


STU:6BG Lytix Biopharma AS STU:6BG
31 GF Score
Price €0.82
GF Value €0.01
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS EPS (Basic)?

Lytix Biopharma AS STU:6BG +2.00% 31 EPS (Basic) is €-0.09 as of Mar. 2026. GuruFocus rates STU:6BG with a GF Score™ of 31/100 and a GF Value™ of €0.01. The stock has 2 warning signs investors should review.

Lytix Biopharma AS's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.09.

Lytix Biopharma AS's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.09.

Lytix Biopharma AS's EPS without NRI for the three months ended in Mar. 2026 was €-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.09.

During the past 3 years, the average EPS without NRI Growth Rate was 14.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Lytix Biopharma AS's highest 3-Year average EPS without NRI Growth Rate was 14.50% per year. The lowest was -26.30% per year. And the median was -6.30% per year.

Lytix Biopharma AS  (STU:6BG) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lytix Biopharma AS EPS (Basic) Related Terms

Lytix Biopharma AS EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS EPS (Basic) Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -0.14 -0.13 -0.19 -0.15 -0.07

Lytix Biopharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.01 -0.03 -0.02 -0.03
STU:6BG
31GF Score
Lytix Biopharma AS STU:6BG
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lytix Biopharma AS's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-5.068-0)/68.534
=-0.07

Lytix Biopharma AS's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.324-0)/76.900
=-0.03

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.09 mean?
Lytix Biopharma AS (STU:6BG) has a EPS (Basic) of €-0.09 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lytix Biopharma AS and its competitors.
Is Lytix Biopharma AS's EPS (Basic) too high?
Lytix Biopharma AS's current EPS (Basic) is €-0.09. Overall, Lytix Biopharma AS has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's EPS (Basic) compare to VRTX and REGN?
Lytix Biopharma AS's EPS (Basic) of €-0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current EPS (Basic) is €-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Lytix Biopharma AS (STU:6BG) has a current EPS (Basic) of €-0.09. The stock's GF Value™ is €0.01, compared to a current price of €0.82 — trading 8060% above its estimated fair value. The current EPS (Basic) is €-0.09. Lytix Biopharma AS's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Lytix Biopharma AS (STU:6BG), the current EPS (Basic) is €-0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (STU:6BG) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of €0.82 is trading 8060% above its estimated GF Value™ of €0.01.

Key valuation signals for STU:6BG:

  • EPS (Basic): €-0.09
  • GF Value™: €0.01 vs. price of €0.82 (8060% above fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the STU:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Other Exchanges LYTIX:Norway
Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
31GF Score

Get the complete analysis for STU:6BG

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.82
Price
€0.01
GF Value